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Abstract—A Deep Autoencoder based content retrieval algo-
rithm is proposed for prediction and differentiation of cancer
types based on the presence of epigenetic patterns of DNA
methylation identified in genetic regions known as CpG islands.
The developed deep learning system uses a CpG island state
classification sub-system to complete sets of missing/incomplete
island data in given human cell lines, and is then pipelined with
an intricate set of statistical and signal processing methods to
accurately predict the presence of cancer and further differenti-
ate the type and cell of origin in the event of a positive result.
The proposed system was trained with previously reported data
derived from four case groups of cancer cell lines, achieving
overall Sensitivity of 88.24%, Specificity of 83.33%, Accuracy
of 84.75% and Matthews Correlation Coefficient of 0.687. The
ability to predict and differentiate cancer types using epigenetic
events as the identifying patterns was demonstrated in previously
reported data sets from breast, lung, lymphoblastic leukemia and
urological cancer cell lines, allowing the pipelined system to be
robust and adjustable to other cancer cell lines or epigenetic
events.
Index Terms—Deep Learning Network, Autoencoder, Cancer
Prediction, Classification, Retrieval Algorithm
I. INTRODUCTION
Significant progress has been made in understanding crucial
regulatory mechanisms responsible for the development and
progression of cancer at a cellular and molecular level, through
genetic alterations such as DNA mutations and disruptions
in epigenetic mechanisms including DNA methylation and
histone modifications [1]. Cancer rates have been progressively
increasing, with the latest statistics from Cancer Research UK
to have reported more than 350,000 new cases diagnosed
in the UK [2], of which more than 40% could have been
prevented. Cancer research has been significantly progressing
with advances in more effective treatments and screening
methods, however there is still a pressing need for more
targeted methods to be available for monitoring of cancer
progression and prevention of treatment resistance that would
help control the disease and improve survival rates. With this
goal, cancer diagnostics have been evolving with findings
from ongoing clinical trials providing strong evidence on the
importance and translational significance of cancer specific
biomarkers aiming towards more precise cancer prediction
systems and monitoring schemes [3].
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Fig. 1. Representation of a genetic region with a CpG site and methy-
lated/unmethylated cytosines indicated in red and blue respectively.
Given that cancer mortality rates are higher for patients
diagnosed with advanced staged disease, early diagnosis of
progressive disease and personalisation of treatment is essen-
tial to achieve better response and therefore higher chances of
prognosis. The use of well-defined epigenetic biomarkers of
predictive and prognostic value, such as DNA methylation,
is essential to be considered in the panel of markers for
monitoring of cancer development and treatment efficacy, due
to their role in critical pathways and regulatory mechanisms
of gene expression [4], [5].
Studies have indicated that aberrations in regulatory areas
of tumour suppressor genes or oncogenes can be caused by
disruptions in DNA methylation patterns, in genome-wide
regions as well as genetic regions with high concentration of
C and G bases, also known as CpG islands, leading to ’gene
silencing’, affecting critical switching mechanisms related to
DNA repair and tumour suppression [6]. Most CpG islands are
located within the 5’ region of expressed genes although they
can also be found near the 3’ region, with DNA methylation
to occur most commonly at the cytosine base of DNA, defined
by the addition of a methyl group (CH3) to the C-5 position,
as shown in Fig. 1. Therefore, in combination with genetic
mutations, detection of DNA methylation aberrations is of
great importance for the development of future generation
of closed-loop cancer monitoring systems, combining sensing
modalities through Lab-on-CMOS systems in combination
with data analytics and classification algorithms [7]–[9].
While CMOS based sensor technologies have been proven
very effective for diagnostic applications given the inherent
advantages of speed, scalability, low cost and the capability
to integrate sensing and processing units in System-on-Chip
interfaces [10]–[13], the growing requirements for processing
of large data sets has created a unique opportunity for machine
learning algorithms to be incorporated into existing systems
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2given the requirements for real-time analytics and process-
ing of large data sets. For cancer diagnostics in particular,
such synergy is foreseen to allow for the development of
more precise, adaptable, intelligent and self-learning systems,
assisting diagnosis and prediction of cancer risk through
the advancement of bioinformatics frameworks, reducing the
inherent complexities in analysis of large-scale data. Recently,
numerous methods have started to explore the use of DNA
methylation patterns analysed from thousands of cancer genes,
using classical and advanced machine learning algorithms,
to create systems that can predict and differentiate cancer
types [14]–[17]. These state-of-the-art methods present unique
ways of exploring methylation patterns, but miss out on
using core CpG island attributes including the occurrence of
dinucleotides, DNA energies of octamers and other distinct
features to provide rich, additional information for resilient
learning of CpG differences.
In this paper, a deep learning system was developed for
prediction and classification of DNA methylation patterns,
used as the distinguishing factors between healthy and of can-
cerous origin data sets. The system incorporates the use of an
algorithm for identifying and completing missing CpG island
states and then processes the extracted island information,
identifying essential features required for the differentiation of
data using well-defined mathematical algorithms. The ability
to learn and autonomously distinguish various cancer types
has been achieved through the use of a Deep Autoencoder
and the combination of an island state prediction algorithm
and of statistical methods. The efficiency of the system was
demonstrated for four cancer types, showing that the proposed
method can selectively isolate relevant features and differenti-
ate between each other, ensuring robustness of the system and
adaptability in different data sets.
II. MACHINE LEARNING FOR TUMOUR CLASSIFICATION
Tumor classification based on machine learning algorithms
using DNA methylation as a recognition pattern has been a
fast growing area of research, with recently reported work
predominantly based on the use of learning models and di-
mensionality reduction methods to locate and then predict the
presence of DNA methylation in given data sets. Specifically,
Zhongwei et al. [14] used high dimensional DNA methylation
data, obtained from the Illumina 27k array to predict the
presence or absence of breast cancer in a given cell type. The
learning model was based on identifying CpG island methy-
lation points in cell lines as the feature set, through a stack
of Random Boltzmann Machine (RBM) layers to produce a
deep learning structure, while reducing dimensionality of the
feature set. The model first selected the best 5,000 features
based on variance from a set of over 27,000 features and
subsequently used four RBM layers to reduce the number
of features to 10-70, followed by classification of generated
features, suggesting that using a stack of RBMs combined with
Self Organised Maps (SOM) to cluster, achieved better fea-
ture selection compared to more classical methods including
Principal Component Analysis (PCA), K-means and Gaussian
mixture model (GMM), with an overall prediction error rate of
2.94% extracted from one database for a single cancer binary
classification. Followingly, CancerLocator was proposed as a
prediction method for the presence and location of tumours
using a binomial probabilistic model, creating a link between
circulating cell-free DNA (cfDNA) in blood samples and
genome wide DNA methylation [15]. Although recent methods
have proposed multi-cancer classification methods [16], the
CancerLocator model demonstrated good results for different
cancer types in real and simulated data, as compared to
Random Forest (RF) and Support Vector Machine (SVM).
Concurrent work on DNA methylation for diagnosis of cancer
types was also demonstrated by Hao et al. [17], using the Least
Absolute Shrinkage and Selection Operator (LASSO) multino-
mial distribution, achieving classification of four cancer types
with high accuracy.
Previously reported algorithms have not taken however into
account the effect of missing data in CpG island features
for DNA methylation prediction. Recently proposed deep
learning methods have been illustrated to determine missing
CpG island states, including examples by [9], [18]. These,
in combination with highly advanced feature-selection algo-
rithms using deep learning systems, could provide substantial
improvements on performance characteristics and accuracy
of data prediction. The proposed system presented here is
based on a previously developed DNA methylation prediction
algorithm for classification of DNA methylation states using
a Deep Belief Network [9], introducing as a new feature the
novel characteristic of using a Deep Autoencoder based deep
learning content retrieval algorithm to predict the presence
of cancer types in previously confirmed cancer cases, with
an additional feature of classification of DNA methylation
values as the differentiating factor. Through this approach
it is therefore offering enhanced accuracy of prediction by
completing missing or incomplete data in the data sets, which
tend to be typically the origin for accuracy variation.
III. UNDER STUDY DATA-SETS
Four categories of cancer types and cell lines in particular
were used in this study to demonstrate efficacy of the proposed
method, obtained from a number of previously reported data-
sets:
• Breast cancer: With a lifetime incidence risk of 12%,
and 20-30% of diagnosed and treated patients to relapse
in the form of an aggressive metastatic disease, breast
cancer is one of the most common cancer types, raising
even more the importance to be studied and classified.
Obtained from [19], data from 30 samples were used,
equally divided in 2 pairs of 15 representing healthy and
cancerous cells respectively.
• Lung carcinoma: Being one of the most frequently de-
tected cancer types, lung cancer is also linked to consid-
erably low survival rates. Obtained from [20], a database
with an extensive set of five lung cancer subtypes was
used, including 124 tumour and 12 healthy samples.
• Lymphoblastic leukemia: Procured from [21], this data-
set provides samples from B-cell precursor acute lym-
phoblastic leukemia (pre-B ALL), one of the most com-
mon types of pediatric cancer [22]. 92 data samples were
3used, 46 of which were derived from tumor samples and
46 from remission samples.
• Urological tumors: Attained from [23], this data-set com-
prises of data sets from 16 healthy and 67 cancerous sam-
ples. The data-set is further divided into three subtypes:
kidney with 6 healthy and 17 cancer cells; bladder with 5
healthy and 25 cancer cells; and prostate with 5 healthy
and 25 cancer cells.
In total, 341 samples were used to test the efficacy of the
proposed system, of which 252 were tumor derived samples
with the rest being cancer free, with specific CpG methylation
profiles of human cells extracted from the Illumina Human450
BeadChip platform [24]. After multiple tests with various
ratios being performed, 75% of the total number of samples
were selected to be used for training, 9% for validation and
16% for testing, with the selection of samples percentages
to have been a result of optimisation during testing while
avoiding overfitting to occur.
Each of the samples in the first three data-sets contained
approximately 485,577 CpG islands, with a small variation in
the urological tumor data sets that contained 485,512 CpG
islands. Random sample selection was performed 10 times
and the results were averaged with tests results derived from
a K-fold validation. In each specimen of every category,
a number of CpG islands was missing as data may have
been lost, incorrectly detected or processed. In previously
reported methods for distinguishing cancer types, in the event
of a missing data set derived from an island occuring, data
from the same island from all samples were consequently
discarded, causing loss of essential features which could have
otherwise provided useful information to the learning network.
This challenge was tackled with the proposed solution, with
the following sections to present the methods and resulting
performance of the proposed system, overcoming the issue of
incomplete data bypassing.
IV. PROPOSED DEEP LEARNING SYSTEM
The proposed cancer prediction and classification algorithm
is illustrated in Fig. 2. It first uses the previously reported
methylation prediction method [9] to determine the state
of missing/incomplete CpG islands, providing comprehensive
information derived from given cell lines. As each cell line
possesses large features (485,577 islands), the collection of all
samples can be considered as equivalent to a big data set. As
with any big data structure, a series of intricate and connected
feature extraction and reduction methods are needed to reduce
computational complexity, reduce time and increase efficiency
of data distribution. The island descriptors are processed and
reduced by a set of methods described in Section IV-C,
and once a reduced state is obtained, a Deep Autoencoder
network is implemented, as described in Section IV-D, to
perform further dimension reduction and learning. Subsequent
dimension reduction using a Deep Autoencoder is cemented
to the learning network by an important factor, providing the
ability to improve its own efficiency in predicting the presence
of cancer and classifying its type.
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Fig. 2. Proposed Deep Autoencoder framework incorporating the DNA
methylation state prediction system.
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Fig. 3. Deep Belief Network (DBN) structure used for the prediction of DNA
methylation state.
A. Prediction of missing CpG methylation data
All missing islands, incorrectly obtained data and incom-
plete data-sets are completed using the methylation prediction
algorithm described in [9], to provide comprehensive informa-
tion to all data sets, so that all cell lines contain uniform and
complementary information.
The algorithm described in [9] obtained methylation char-
acteristic features for every CpG island and included parallel
image-analogous islands descriptors to derive the histogram of
oriented gradients (HOG) features, which were then used as
inputs of the Deep Belief Network (DBN) to classify islands
as either methylated or unmethylated. A representation of the
DBN structure can be seen in Fig. 3. This algorithm is used as
it is highly accurate and consistent, and does not depend on the
area of the genome or chromosome under test. Training of the
island classification system is then performed using data from
the ENCODE consortium [25], while classification is achieved
for the data-set described in Section III.
Prior to the classification, the average value of all hyper-
methylated and hypomethylated islands of all cell lines are
separately obtained. All islands that possess a methylation
value greater than 0.5 are considered as ’hypermethylated’ and
those below 0.5 as ’hypomethylated’. For islands classified
as methylated, the average value of a hypermethylated state
is substituted, while for those classified as unmethylated, the
average value is hypomethylated. Thus, each cell line now
has comprehensive information for all 485,577 islands through
normalisation of all data sets, preventing potential loss of
essential data that used to be eliminated by previously reported
methods, while allowing for detection and differentiation of
various cancer types.
4B. Observation of features and preliminary interpretations
Before performing feature transforms, the cell lines are
visually analyzed. On the basis that cancer cells possess local
increase (hypermethylation) but global reduction (hypomethy-
lation) of DNA methylation [1], after collecting comprehensive
information for all cell lines, heatmaps for various cancerous
and healthy cells were obtained and plotted in Fig. 4, as a
method of visually illustrating the increase/decrease of methy-
lation. It is evident that global and local differences appear
in the cases of breast, lung and leukemia cells. Interestingly,
when all cases are viewed as a complete image, cancer cells
global methylation intensity appears to be high even though the
average values are not. This is attributed to the fact that cancer
cells have large areas of hypermethylation (regions appearing
in yellow) locally dispersed with regions of hypomethylation
(regions appearing in blue), causing the average to balance out.
Healthy cells tend to maintain an average value in methylation
across all regions (seen by the large green regions). This
concurs with the expectation previously stated. Of the above
three cell lines, the difference between leukemia’s cancer
and healthy cell lines is noticeably visible and leads to the
observation that classification of leukemia samples is expected
to be highly accurate. This trend is not followed as clearly in
the case of urological samples, as the cancerous and healthy
cells seem to possess similar heatmaps leading to identical
feature sets. Thus, it is expected that the classification of
urological samples may not achieve the desired results for
the given database. The heatmaps provide useful information
and a visual representation of the data-sets, and to accomplish
robust learning of all the data-sets, the next section describes
the extraction, processing and selection of high calibre features
needed to feed the Autoencoder system.
C. Feature processing and reduction
For a neural network to form a good mapping distribution
of features, it is essential that quality descriptors are used
by transforming features into standard and normalized values
so that each neuron in the network creates a good weighted
response to its inputs. Feature selection and extraction (col-
lectively called ’reduction’ in this study) is used to map high
dimension vectors to lower dimensions in order to reduce
computational cost and prevent data overfitting.
The feature processing and reduction flowchart can be seen
in Fig. 5, illustrating the Deep Autoencoder network layers
described in Section IV-D. The first step involves a quality
control of all the islands by obtaining p-values across all
points, extracted by obtaining a ratio of the signal value for
each probe (value) to the background signal obtained from the
negative probe values, as illustrated in [26]. The p-value test is
performed for all the island samples and a reliable feature set is
then obtained. All signal values exceeding 0.01 are discarded
while those below that value are kept as reliable quantities,
before normalization of all the features is performed using the
standard score given by:
XNorm =
X − µ
σ
(1)
where µ and σ represent the mean and standard deviation
of each feature column. To scale, unity based normalisation is
obtained from XNorm as:
XScaled =
XNorm −XMin
XMax −XMin (2)
Reduction of features is then performed by using a low
variance filter to eliminate all feature columns that possess low
variance with respect to one another so that unwanted features
that provide no useful information for differentiation between
cancer classes are eliminated. This is then followed by the
use of the Partial Least Squares (PLS) algorithm [27], which
in similar function as Principal Component Analysis (PCA),
is used to compress the descriptor set to 100,000 features
by creating a new feature space. PLS was used as it has
been reported as a very efficient method for dimensionality
reduction of genomic data, contrary to PCA, through the
use of supervised covariance matrices [27]. Thus, the low
variance filter eliminates features, while the PLS creates a
new and reduced feature space. The reduced features are then
clustered and reduced once again using Stochastic Neighbour
Embedding (SNE) [28], a well-known algorithm for reduction
of high volume data-sets. The algorithm seeks to minimize
the cost function C of asymmetric probability pij and induced
probability qij , which were defined as by:
pij =
exp(−d2ij)∑
k 6=i exp(−d2ik)
(3)
where d2ij is the squared Euclidean norm of two high
dimensional points xi and xj .
qij =
exp(−||yi − yj ||2)∑
k 6=i exp(−||yi − yk||2)
(4)
where yi is a low dimensional object.
C =
∑
1
∑
j
pij log
pij
qij
(5)
As described in [28], the gradient can be simplified to:
∂C
∂yi
= 2
∑
j
(yi − yj)(pij − qij + pji − qji) (6)
This helps significantly in forming clusters based on neigh-
bours, thus combining and reducing the number of features
from 100,000 to 10,000. Two different extraction algorithms
(PLS and SNE) were used to reduce computational intensity
and time, while producing the best features to be further
utlized by the Autoencoder network.
D. Deep Autoencoder Network
The learning algorithm used in this research, the Deep
Autoencoder, represents an unsupervised neural network that
was created for the purpose of allowing efficient sparse
representation of large data sets (encoding) and in time, the
method has gained prominent significance as a learning tool.
A basic Autoencoder design can be seen in Fig. 6(a) which
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in black represent the method used, while the numbers in blue represent the
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forms a weighted structure similar to that of a Multilayer
Perceptron, as it consists of two important halves, encoding, to
compress the data into a sparse representation and decoding,
to reconstruct the data to a form similar to the input.
Let xi represent the input data and zi represent its encoded
form. As explained in [29], the relation between them is given
by:
zi = s(W1xi + b1) (7)
where W is the weight vector, b is the bias and s is
the activation function. Essentially, z is the encoded sparse
representation of x. In the decoding half, z is used to form
the reconstructed output x˜i, which is given by:
x˜i = s(W
′
2zi + b
′
2) (8)
The sum of squared differences is the optimization function
used. This is defined as:
J(W1,W2, b1, b2) =
∑
i
(
x˜i − xi
)2
=
∑
i
(
s(W ′2zi + b
′
2)− xi
)2
=
∑
i
(
s(W ′2(s(W1xi + b1)) + b
′
2)− xi
)2
(9)
To make sure that the weights and bias are optimized to
produce x˜i that is very close to xi, the sum function defined
in Eq. 9 is minimized using Stochastic Gradient Descent. By
using multiple layers of Autoencoders, a Deep Autoencoder
network is created, consisting of two symmetric Deep Belief
Network (DBN) layers, in which the first DBN half forms
the encoding system, while the second DBN half forms the
decoding system. A representation of such topology can be
seen in Fig. 6(b), whereby each of the two DBNs consist of
6xx
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Fig. 6. (a) A basic Autoencoder consisting of an encoding and decoding
layer; (b) Representation of a Deep Autoencoder consisting of two halves,
each comprising a Deep Belief Network.
multiple constituent layers of RBMs for a Deep Autoencoder
and the layer z is used with a logistic or some other non-linear
activation function to form the neural network classifier.
In this research, the network consists of three layers map-
ping 10,000 descriptors in the first layer to 200 in the third.
Together, these layers form an efficient neural network ca-
pable of CpG methylation feature classification and cancer
type differentiation. Krizhevsky’s method for image classifi-
cation [30] served as the primary inspiration for incorporating
Deep Autoencoders, as this work uses a Deep Autoencoder
network to produce a content based classification of images
from a multitude of classes and by using sparse ’codes’ derived
from large image features, a robust algorithm is produced.
The unsupervised intermediate layers in the proposed network
use a sigmoid activation function, while the supervised output
layer uses a softmax function and classifies the cells into eight
different categories. Learning rates between each iteration
(epoch) are adapted, so that learning happens quickly in the
first couple of epochs and fine tuning happens later, with
Stochastic Gradient Descent to be used to minimise the error
function. The neural network distinguishes between four cell
types, and healthy/cancerous states, thus creating eight output
classes to classify into.
E. Technical Implementation
All aspects of data cleaning, analysis, feature extraction
(processing and reduction) are implemented using MATLAB
and its associated toolboxes, with some algorithms being
tested in Python, specifically the scikit-learn machine learning
library [31]. The Deep Autoencoder network is implemented
using the Keras open source library [32] running on Theano.
Experiments were run in a 16GB RAM CPU.
F. Performance Metric
The performance of the system was evaluated based on
the four criteria: Sensitivity (SE), Specificity (SP ), Accu-
racy (ACC) and Matthew’s Correlation Coefficient (MCC).
These are calculated based on the accurate identification of
positive (cancerous) or negative (healthy) cell lines. A True
Positive (TP ) would indicate that the cancerous cell line is
identified correctly, while a False Positive (FP ) indicates that
a cancerous cell line is identified as healthy. Conversely, True
Negatives (TN ) and False Negatives (FN ) are calculated for
healthy cell lines. The metrics are defined by the following
equations:
SE =
TP
TP + FN
(10)
SP =
TN
TN + FP
(11)
ACC =
TP + TN
TP + TN + FP + FN
(12)
MCC =
(TP ∗ TN)− (FP ∗ FN)√
(TP + FN)(TN + FP )(TP + FP )(TN + FN)
(13)
While ACC of the system is the most important perfor-
mance indicator, the MCC plays an equally important role
in evaluating its performance as there are unequal numbers
of healthy and cancerous cells. SE and SP determine the
system’s ability to separately identify healthy or cancerous
cells, and gives a good indication of its ability.
V. RESULTS AND DISCUSSION
An eight-category classification method is implemented to
determine (i) whether a cell line is healthy or cancerous, and
(ii) to distinguish the type of cell (and therefore cancer type
and state) it associates with. From the demonstrated analysis,
the achieved overall Sensitivity (SE) of the developed system
was 88.24%, followed by Specificity (SP ) of 83.33%, Accu-
racy (ACC) of 84.75% and Matthews Correlation Coefficient
(MCC) of 0.687. These values are higher for multi-cancer
classification compared to previous state-of-the-art methods,
as observed in Table I, and the ACC reported is for both the
highest individual cancer class as well as for multi cancer type
classification.1
TABLE I
ACHIEVED ACCURACY (ACC) AND COMPARISON WITH OTHER
PUBLISHED WORK
Method No. of Cancer Types Single ACC Multi ACC
Deep Autoencoder [This work] 4 (8 classes) 93.33% 84.75%
RBM + SOM [14] 1 (2 classes) 97.06% -
Binomial Prob. [15] 3 (4 classes) 83.5% 73.5%
The results for the developed cancer classification method
are plotted in a confusion matrix, shown in Fig. 7 and for each
cancer type, the metrics obtained for different cancer types are
reported in Table II. From Fig. 7 and Table II, it is observed
that healthy cells of breast and white blood cells (leukemia)
are classified very well, leading to 100% specificity. In the
case of lung samples, cancerous cells are classified very well,
leading to a high sensitivity (94.73%) and overall classification
performance, white blood cells (leukemia) produce the best
accuracy and MCC, indicating that prediction of cancer and
1Multi cancer ACC is outlined only for methods that classify more than
one cancer types. It is more difficult to place samples into multiple classes
when more than one cancer type is studied, as compared to classifying a single
cancer type that has only two options for (mis)classification. For methods that
classify a single cancer type, including [14], their total ACC is reported for
Single ACC, while methods that use multi cancer classification report the
highest individual ACC for this metric.
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Fig. 7. Confusion matrix representing the accuracy of classification for each
cancer type data-set. The higher the values of the diagonal elements (towards
yellow), the more precise the classification. The figure illustrates that breast,
leukemia and lung cell derived data-sets have little to no mistakes observed
in classification, while urological cells (both healthy and cancerous) tend to
be more often misclassified.
its classification is very efficient. This was foreseen in Sec-
tion IV-B as leukemia cells possess clear differences in DNA
methylation patterns, seen in their corresponding heatmaps.
Breast and lung data-sets also perform fairly well with good
accuracy and MCC values. Compared to other data sets,
urological cell lines produced average scores as forecasted
in Section IV-B. This is attributed to the fact that healthy
and cancerous cell lines for this type do not possess succinct
properties in DNA methylation derived from the reported data-
set used that can be used for good differentiation.
TABLE II
CLASSIFICATION METRICS OF EACH CANCER CELL TYPE
Cell Type Sensitivity Sensitivity Accuracy MCC
Breast 80% 100% 87.50% 0.775
Leukemia 75% 100% 93.33% 0.829
Lung 94.73% 75% 91.30% 0.697
Urological 71.42% 50% 61.53% 0.219
It is reported in [14] that for a single cancer cell (breast
cancer cell) classification, the accuracy is 97.06% and is very
close to the results obtained in the case of leukemia and lung
cancer obtained in the proposed method. The reason for higher
accuracy in this research can be attributed to the fact that this
method performs classification only for a single cell type (two
classes) providing fewer opportunities for misclassification,
while the proposed method distinguishes four cell types (eight
classes). Nevertheless, for a multi-class system, the proposed
method produces excellent results for individual cases, as
compared to a single cancer classification system.
Whereas, in [15], it was reported that the overall accuracy
obtained for four classes (three cancer types, and one non-
cancer category) was 73.5% with the presented method to
produce an accuracy that is significantly better for four cancer
types, with each healthy cell not being categorized into a single
class, as proposed in [15], with the highest individual accuracy
for a single class obtained for the non-cancer class, with an
ACC of 83.5%, the proposed system achieves one of the
highest reported individual ACC of 93.33% generated by the
leukemia cell derived data-sets. The difference in error rates
can be credited to the fact that the learning method described
in [15] uses a binomial probability distribution model, whereas
the proposed method uses multiple probability models (deep
learning layers) to better identify differences between classes.
The proposed method also offers the novel distinction
of using DNA methylation prediction to estimate values of
missing islands, which would have otherwise been ignored,
preserving more information from partial data while providing
a better overall accuracy. While the goal of this research is
the development of a strong machine learning algorithm for
classification and differentiation of cancer types, which has
been successfully demonstrated; it is also inferred that access
to a larger and unified DNA methylation database would
have improved the system’s ability to classify some individual
cases, as in the example of urological tumors, which would
be within the scope of a future investigation.
VI. CONCLUSION
A deep learning based cancer prediction and classification
system has been described in this paper, using a prediction
assembly to provide comprehensive information for data-sets
derived by cancerous/healthy cell lines. Forming a correlation
with cancer specific biomarkers and their prevalence in gene-
specific and genome-wide genomic regions, patterns of DNA
methylation were used as indicators. In conjugation with a
combination of feature processing and dimensionality reduc-
tion methods, coupled with a Deep Autoencoder network, the
proposed system produces a robust machine learning arrange-
ment, capable of classifying four given cancer types. The
intricate, yet well-defined pipeline of state-of-the-art-methods
applied to complete CpG island features of human cell lines
allows the system to select the best features, producing an
overall accuracy of 84.75% to distinguish four cancer types
and is significantly better than the closest work in literature
reported to classify three cancer types.
The proposed work is a Minimum Viable Product (MVP)
that provides the required functionality to distinguish cancer
types, offering a visual representation of the generated classi-
fication outcome. The developed method is envisioned to be
further adapted in the artificial intelligence based systems that
would provide decision support to healthcare professionals,
offering methods for improving patients stratification and
diagnosis. In conjugation with cancer diagnostic and prediction
systems, computational models will thus allow for the creation
of a unified big data driven platform to aid and personalise
cancer diagnosis and predict response of patients to treatment,
offering the clinicians further insight, allowing patients di-
agnosed with cancer to undertake treatment in a faster and
more effective way. This work will contribute towards this
envisioned future, improving cancer care and progressing the
future of technologies in cancer research.
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